Search academic texts

Information × Registration Number 0216U009203, 0115U001379 , R & D reports Title Peculiarities of "Ferroplat" interaction with structural and functional components of sensitive and resistant tumor cells popup.stage_title Head Chekhun Vasyl Fedorovych, Registration Date 30-12-2016 Organization R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology popup.description2 It is established that the Feroplat treatment led to a decrease in the rate of oxygen uptake in MCF-7 and T47D cell lines 26% and 25%, respectively (p<0.05). In the cells of a high degree of malignancy this mean under Feroplat impact was reduced by 38-40%. Incubation of cells MCF-7 and T47D with the agent also resulted in the reduction of phospholipid cardiolipin level by 15 and 16% (p <0.05), and in the MDA-MB-231, MCF-7/CP and MDA-MB-468 by 29%, 30% and 32%, respectively. In addition, Feroplat caused lowering of magnesium lactate levels in cells MCF-7 and T47D to 21-29% and 14-24%, respectively, while in the MDA-MB-231, MDA-MB-468 and MCF-7/CP - by 34-38% and 32-35%, respectively. In this case, under the agent treatment the level of glucose was increased in the cells of low-grade malignancy by 20-23% (p <0.05), and in a high degree of malignancy cells and drug resistance phenotype - by 31-36%. However, the nanocomposite did not affect on lactate dehydrogenase activity in all studied cell lines of breast cancer. Thus, the results of studies have shown that one of the mechanisms of Feroplat action is its impact on the energy metabolism of cells due to inhibiting mitochondrial oxidative phosphorylation and glycolysis. This is evidenced by reduction in oxygen uptake rate, the levels of cardiolipin, magnesium lactate and increase of glucose levels under the influence Feroplat in the cells of high malignancy degree and with drug resistant phenotype. On in vivo model of sensitive Guerin carcinoma Feroplat pharmacokinetics as compared to cisplatin was investigated. It was found that Feroplat is more actively accumulates in the tumor and shows a lower nephrotoxicity. Theese data is a fundamental basis for Feroplat usage for validated pathogenetic therapy of malignant tumors. Product Description popup.authors Кунська Любов Миколаївна Лозовська Юлія Валеріївна Лук'янова Наталія Юріївна Павлова Анна Олександрівна Петрановська Алла Леонідівна Тодор Ігор Миколайович Чехун Василь Федорович Швець Юлія Вікторівна popup.nrat_date 2020-04-02 Close